MX360640B - Diagnosis e imagenologia de cancer. - Google Patents
Diagnosis e imagenologia de cancer.Info
- Publication number
- MX360640B MX360640B MX2012010119A MX2012010119A MX360640B MX 360640 B MX360640 B MX 360640B MX 2012010119 A MX2012010119 A MX 2012010119A MX 2012010119 A MX2012010119 A MX 2012010119A MX 360640 B MX360640 B MX 360640B
- Authority
- MX
- Mexico
- Prior art keywords
- imaging
- mammal
- cell cycle
- cancer diagnosis
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para crear imagen de una enfermedad o condición en un mamífero, que incluye los pasos de: administrar una cantidad terapéuticamente efectiva de un inhibidor de ciclo celular para detener efectivamente la proliferación de células eucarióticas en un punto de control del ciclo celular entre las fases G1 y S, detener la administración del inhibidor de ciclo celular durante un periodo, administrar un marcador el mamífero y crear imagen del mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30903010P | 2010-03-01 | 2010-03-01 | |
PCT/US2011/026416 WO2011109262A2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012010119A MX2012010119A (es) | 2012-09-12 |
MX360640B true MX360640B (es) | 2018-11-09 |
Family
ID=44542787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012010119A MX360640B (es) | 2010-03-01 | 2011-02-28 | Diagnosis e imagenologia de cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9427429B2 (es) |
EP (1) | EP2542155B1 (es) |
JP (1) | JP6017964B2 (es) |
KR (1) | KR101821343B1 (es) |
CN (1) | CN102781316B (es) |
AU (1) | AU2011223883B2 (es) |
CA (1) | CA2787673A1 (es) |
ES (1) | ES2557407T3 (es) |
HK (1) | HK1179143A1 (es) |
IL (1) | IL221035A0 (es) |
MX (1) | MX360640B (es) |
SG (2) | SG183114A1 (es) |
WO (1) | WO2011109262A2 (es) |
ZA (1) | ZA201205377B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1778619B1 (en) * | 2004-08-20 | 2012-04-04 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
WO2011109262A2 (en) | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
EP3487516A1 (en) * | 2016-07-19 | 2019-05-29 | Bristol-Myers Squibb Company | Radioligands for imaging the ido1 enzyme |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
AU2018221722B2 (en) | 2017-02-15 | 2022-02-03 | Cavion, Inc. | Calcium channel inhibitors |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1219609A (en) | 1968-07-19 | 1971-01-20 | Koninklijke Pharma Fab Nv | Diphenylmethoxyethylamino derivatives |
US3732247A (en) | 1970-08-14 | 1973-05-08 | Robins Co Inc A H | 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms |
US4091103A (en) | 1976-06-23 | 1978-05-23 | Ciba-Geigy Corporation | Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives |
JPS59161392A (ja) | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | ジヒドロピリジン誘導体及びその製法 |
US4906646A (en) | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
US4885284A (en) | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
FR2601366B1 (fr) | 1986-07-10 | 1988-11-25 | Andre Buzas | Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant. |
ATE128623T1 (de) | 1988-08-02 | 1995-10-15 | Nissan Chemical Ind Ltd | Mittel zur verbesserung von arzneimitteleffekten für antitumormittel. |
JP2850376B2 (ja) | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | 抗癌剤薬効増強剤 |
FR2636946B1 (fr) | 1988-09-23 | 1990-11-02 | Lipha | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
EP0467435A3 (en) | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6413967B1 (en) | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
EP0848614B1 (en) | 1995-09-08 | 2006-04-26 | Beth Israel Deaconess Medical Center | Isolation of microdomains of caveolae and gpi-anchored proteins |
ATE256110T1 (de) | 1995-09-15 | 2003-12-15 | Neurosearch As | Piperindinverbindungen als calcium-kanal-blocker |
SK109198A3 (en) | 1996-02-14 | 1999-06-11 | Isis Pharmaceuticals Inc | Sugar-modified gapped oligonucleotides |
CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
US6191156B1 (en) | 1997-04-11 | 2001-02-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating bladder dysfunction |
US6703374B1 (en) * | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
ES2274588T3 (es) | 1997-12-03 | 2007-05-16 | MERCK & CO., INC. | Composiciones de los canales de calcio a baja tension y procedimientos correspondientes. |
EP1036170A1 (en) | 1997-12-05 | 2000-09-20 | Loyola University Of Chicago | T-type voltage-gated calcium channels and method of using same |
JPH11246417A (ja) | 1998-03-04 | 1999-09-14 | Nissan Chem Ind Ltd | 糖尿病性腎症治療用医薬組成物 |
US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
WO2000015845A1 (en) | 1998-08-26 | 2000-03-23 | South Alabama Medical Science Foundation | T-type calcium channel |
US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
CA2369588C (en) | 1999-04-07 | 2011-02-08 | Lloyd S. Gray | Anticancer calcium channel blockers |
US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
US7195783B2 (en) | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
WO2001062740A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
ATE357257T1 (de) | 2000-07-27 | 2007-04-15 | Pharmacia Corp | Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
EP1392361A4 (en) * | 2001-05-11 | 2009-08-05 | Univ Texas | THERAPY BASED ON ANTI-CD26 MONOCLONAL ANTIBODIES AGAINST DISORDERS ASSOCIATED WITH CELLS EXPRESSING CD26 |
AU2002328945A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
HU229452B1 (en) | 2002-01-17 | 2013-12-30 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
CA2486622A1 (en) | 2002-05-20 | 2003-12-04 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
CA2499599A1 (en) | 2002-09-17 | 2004-04-01 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
RU2326886C2 (ru) | 2003-03-28 | 2008-06-20 | Ниссан Кемикал Индастриз, Лтд. | Блокатор кальциевых каналов т-типа |
TW200528107A (en) | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
JP2008501633A (ja) | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 癌の診断及び治療のためのCav3アイソフォーム及びそのδ25スプライスバリアントの阻害 |
AU2011203315B8 (en) | 2004-02-11 | 2012-02-16 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
US20070178462A1 (en) | 2004-02-18 | 2007-08-02 | Uebele Victor N | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof |
US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
WO2006003020A1 (en) | 2004-07-02 | 2006-01-12 | L'oreal | Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof |
US20080194669A1 (en) | 2004-08-20 | 2008-08-14 | Gray Lloyd S | T Type Calcium Channel Blockers and the Treatment of Diseases |
US20120264804A1 (en) | 2004-08-20 | 2012-10-18 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
US20100222406A1 (en) | 2007-09-11 | 2010-09-02 | University Of Virginia Patent Foundation | T Type Calcium Channel Blockers and the Treatment of Diseases |
EP1778619B1 (en) | 2004-08-20 | 2012-04-04 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
US7851431B2 (en) | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | T-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
BRPI0716498A2 (pt) * | 2006-08-10 | 2015-01-27 | Oncotherapy Science Inc | Genes e polipeptídeos relacionados a cânceres de mama |
CN101528768A (zh) * | 2006-08-10 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | 与乳腺癌相关的基因和多肽 |
KR20090097188A (ko) | 2006-12-19 | 2009-09-15 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegh-특이적 길항제 |
WO2008137107A1 (en) | 2007-05-02 | 2008-11-13 | Krouse Andrew J | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
CN101854802B (zh) | 2007-09-10 | 2014-12-03 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
JP5029328B2 (ja) | 2007-12-05 | 2012-09-19 | マツダ株式会社 | 自動車の前部車体構造 |
MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
SI2307051T1 (sl) | 2008-07-08 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe |
SG10201402863PA (en) | 2009-06-05 | 2014-10-30 | Tau Therapeutics Llc | Interlaced method for treating cancer or a precancerous condition |
WO2011109262A2 (en) | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
SG11201400526TA (en) | 2011-09-12 | 2014-04-28 | Tau Therapeutics Llc | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
-
2011
- 2011-02-28 WO PCT/US2011/026416 patent/WO2011109262A2/en active Application Filing
- 2011-02-28 KR KR1020127022975A patent/KR101821343B1/ko active IP Right Grant
- 2011-02-28 CA CA2787673A patent/CA2787673A1/en not_active Abandoned
- 2011-02-28 EP EP11751125.3A patent/EP2542155B1/en not_active Not-in-force
- 2011-02-28 SG SG2012055232A patent/SG183114A1/en unknown
- 2011-02-28 MX MX2012010119A patent/MX360640B/es active IP Right Grant
- 2011-02-28 SG SG10201501496TA patent/SG10201501496TA/en unknown
- 2011-02-28 JP JP2012556123A patent/JP6017964B2/ja not_active Expired - Fee Related
- 2011-02-28 US US13/581,390 patent/US9427429B2/en not_active Expired - Fee Related
- 2011-02-28 CN CN201180011495.2A patent/CN102781316B/zh not_active Expired - Fee Related
- 2011-02-28 AU AU2011223883A patent/AU2011223883B2/en not_active Ceased
- 2011-02-28 ES ES11751125.3T patent/ES2557407T3/es active Active
-
2012
- 2012-07-18 ZA ZA2012/05377A patent/ZA201205377B/en unknown
- 2012-07-19 IL IL221035A patent/IL221035A0/en not_active IP Right Cessation
-
2013
- 2013-05-30 HK HK13106393.5A patent/HK1179143A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SG10201501496TA (en) | 2015-04-29 |
IL221035A0 (en) | 2012-09-24 |
AU2011223883B2 (en) | 2015-10-08 |
JP2013521287A (ja) | 2013-06-10 |
WO2011109262A3 (en) | 2011-11-17 |
MX2012010119A (es) | 2012-09-12 |
SG183114A1 (en) | 2012-09-27 |
ES2557407T3 (es) | 2016-01-25 |
EP2542155B1 (en) | 2015-11-04 |
CN102781316A (zh) | 2012-11-14 |
KR101821343B1 (ko) | 2018-01-23 |
US20120321561A1 (en) | 2012-12-20 |
US9427429B2 (en) | 2016-08-30 |
CN102781316B (zh) | 2016-07-06 |
AU2011223883A1 (en) | 2012-09-13 |
JP6017964B2 (ja) | 2016-11-02 |
HK1179143A1 (zh) | 2013-09-27 |
ZA201205377B (en) | 2013-09-25 |
WO2011109262A2 (en) | 2011-09-09 |
KR20130014506A (ko) | 2013-02-07 |
CA2787673A1 (en) | 2011-09-09 |
EP2542155A4 (en) | 2013-07-17 |
EP2542155A2 (en) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX360640B (es) | Diagnosis e imagenologia de cancer. | |
WO2013033396A3 (en) | Fap-activated proteasome inhibitors for treating solid tumors | |
MX2019002774A (es) | Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica. | |
MX2022002786A (es) | Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal. | |
UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
MX2019013263A (es) | Inhibidores de la recirculacion de acidos biliares para el tratamiento de enfermedades hepaticas colestasicas pediatricas. | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
IL223889B (en) | Contrasting side effects associated with the administration of an anti-hyaluronan factor and methods for alleviating or preventing the side effects | |
MX2011012940A (es) | Metodo entrelazado para tratar cancer o una condicion precancerosa. | |
MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
WO2012071369A3 (en) | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease | |
MX2019009539A (es) | Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b). | |
EP2575596A4 (en) | METHODS FOR DETERMINING RENEWAL OF BETA-AMYLOIDS IN BLOOD | |
GB2451987A (en) | Assessment of the effects of topical administration of chemodenervating pharmaceuticals | |
MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
PH12014500990A1 (en) | Methods for treating gout flares | |
UA114699C2 (uk) | Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
EP2734221A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM | |
SG195127A1 (en) | Methods of treating or preventing neurological diseases | |
SG195170A1 (en) | Methods of treating or preventing rheumatic disease | |
GB201022049D0 (en) | Methods | |
WO2014169011A3 (en) | Methods for treating immune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |